Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMost people using Mounjaro for weight loss start to see the scale move within the first four weeks, though meaningful, sustained loss typically builds over three to six months as doses increase. In the SURMOUNT-1 clinical trial, participants lost an average of around 20–21% of body weight over 72 weeks at the highest dose — but the journey is gradual by design, not sudden. Mounjaro (tirzepatide) is a prescription-only medicine and every person's response depends on their starting point, dose, lifestyle and how their body responds to treatment. A GPhC-registered prescriber will assess whether it is clinically suitable for you before any treatment begins.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Treatment begins at 2.5 mg. That first pen exists to let your body settle into tirzepatide's effects, not to deliver dramatic results. Appetite suppression begins quickly (some people notice they feel fuller sooner within days) but the scale moves slowly at this stage. Most people lose somewhere between one and three kilograms in the first month, and some lose less than that. That's not a sign anything is wrong.
A common misconception worth setting aside early: Mounjaro doesn't work like a crash diet. There is no week where you suddenly drop a large amount of weight. The mechanism (slowing gastric emptying, signalling fullness through two gut-hormone pathways) creates a steady reduction in calorie intake rather than a sharp one. The SURMOUNT-1 trial, published in the New England Journal of Medicine, followed participants over 72 weeks, not 72 days. That framing matters.
Lifestyle inputs count from week one. Protein intake, hydration, and some form of movement all influence how your body responds to a calorie deficit. Your prescriber or a dietitian is the right person to advise on what that looks like for you specifically.
Roughly every four weeks, your prescriber reviews your progress and tolerance. If 2.5 mg is well tolerated, the dose moves to 5 mg, then 7.5 mg, and so on up to 15 mg if needed. Weight loss tends to accelerate with each step up. By month three, many people have lost five to eight percent of their starting weight. By month six, those on higher doses are often closer to ten to fifteen percent.
This is the window where most people report that the medicine is clearly working, appetite is meaningfully reduced, portions feel different, and movement becomes easier as weight comes off. The pace at which Mounjaro starts working varies person to person, but months two through six are generally where the trajectory becomes visible.
NICE's appraisal of tirzepatide (TA1026) uses six months on the highest tolerated dose as the formal review point: if body weight has not fallen by at least 5% by then, continuing treatment is reviewed. That threshold is a clinical checkpoint, not a pass/fail, your prescriber weighs the full picture.
It is also worth understanding what the early weeks on Mounjaro feel like practically: gastrointestinal side effects such as nausea, constipation and reflux are most common during dose-increase weeks, then usually ease. Starting at a low dose and stepping up slowly is precisely how the schedule is designed to manage this.
The SURMOUNT-1 trial ran for 72 weeks) roughly seventeen months. The largest losses accumulated between the six-month and eighteen-month marks, as participants reached and sustained higher doses. If you want a clearer sense of how long it typically takes to lose weight on Mounjaro, the evidence from that trial period gives the most complete picture available. Average weight reduction reached around 20–21% of body weight at 15 mg. To put that in concrete terms: for someone starting at 100 kg, that is 20–21 kg lost on average over the full trial period.
Weight loss also tends to plateau as the body reaches a new equilibrium. This is normal physiology, not treatment failure. The plateau typically arrives later on Mounjaro than on lower-efficacy medicines because of tirzepatide's dual GIP and GLP-1 receptor activity, but it does arrive. Continued lifestyle input is what moves things further at that stage.
For context on how tirzepatide's results compare to other licensed options, the broader tirzepatide weight-loss timeline pulls together the evidence across the SURMOUNT programme. And if you want to understand the full clinical picture of what to expect, the realistic before-and-after evidence sets out what the trial data actually shows rather than what social media suggests.
The trial averages are a map, not a GPS coordinate for your journey. Several things push results faster or slower in real life. Starting weight is one: people with a higher BMI often see larger absolute losses but similar percentage losses. Dose reached is another, those who tolerate 15 mg consistently tend to lose more than those who settle at 7.5 mg. Diet quality and activity amplify the medicine's effect rather than replace it; Mounjaro is licensed alongside a reduced-calorie diet and increased activity for good reason.
Metabolic factors matter too. Insulin resistance, thyroid function and medication interactions can all affect the rate of loss. This is why the clinical assessment before starting treatment matters, it shapes the conversation about realistic timelines for your specific situation.
At nume, every repeat order is reviewed by a prescriber before it is approved. That means someone qualified is watching your progress at each stage, not just at the start. If you are wondering whether Mounjaro is right for you, or how the process works, checking your eligibility takes a few minutes and costs nothing. Check your eligibility with our prescribers and get a same-day clinical review.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.